INTRODUCTION
============

Although radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF) is an effective strategy for rhythm control, there remains a substantial recurrence rate.[@B1][@B2][@B3] The majority of AF cases are triggered in patients with paroxysmal AF (PAF) derived from pulmonary veins (PVs), although 10-30% of PAF patients and the majority of patients with persistent AF (PeAF) have non-PV triggers.[@B1][@B4][@B5][@B6] Therefore, post-procedural detection and elimination of non-PV triggers might result in a better clinical outcome. Testing for immediate recurrence of AF after cardioversion is the common method for the detection of AF triggers.[@B7][@B8] However, a post-procedural test for immediate recurrence of AF requires time, isoproterenol infusion,[@B6] sedation, and electrical cardioversion. Moreover, repetitive electrical cardioversion may increase the risk of peri-procedural stroke in high-risk patients.[@B9] Therefore, the clinical value of a post-procedural test for immediate recurrence of AF and additional ablation targeting remaining non-PV foci has not been clearly determined. With the development of a three-dimensional (3D)-electroanatomical software mapping system, the mapping and ablation of frequent atrial premature beats (APBs) has become relatively fast and accurate. Therefore, we hypothesized that non-PV-origin APBs may contribute to AF recurrence after catheter ablation. We defined the provocation of immediate recurrence of APBs (IRAPBs) as the detection of post-procedural frequent APBs (≥6 beats per minute) after electrical cardioversion under isoproterenol infusion (5 µg/min). The purposes of this study were to explore whether post-procedural IRAPB provocation and additional ablation for mappable frequent APBs affect the clinical outcome of AF ablation and whether IRAPB provocation lengthens procedure time or increases the complication rate. We also tested whether the type of induced tachyarrhythmias \[AF or atrial tachycardia (AT)\] and the presence of IRAPB are risk factors for clinical recurrence of AF after catheter ablation.

MATERIALS AND METHODS
=====================

Study population
----------------

The study protocol adhered to the Declaration of Helsinki and was approved by the Institutional Review Board of Yonsei University Health System. All patients provided written informed consent. This study was a single-center retrospective comparison study, and patients were matched 1:1 by age, sex, and AF type. The study included patients with AF (76.5% males; 57.4±11.1 years old) who underwent RFCA between March 2011 and December 2012. The exclusion criteria were as follows: 1) permanent AF refractory to electrical cardioversion; 2) AF with valvular disease (\>grade II); 3) associated structural heart disease other than left ventricular hypertrophy; and 4) prior AF ablation. IRAPB provocation tests were conducted in 100 consecutive patients, who were compared with 100 age-, sex-, and AF-type-matched patients who completed ablation without any induction or mapping test (No-Test group) ([Fig. 1](#F1){ref-type="fig"}). Among them, 67.0% of patients had PAF, and 33.0% had PeAF. 3D spiral computerized tomography (CT) scans (64 Channel, Light Speed Volume CT, Philips, Brilliance 63, the Netherlands) were performed to visually define atrial and PV anatomy in all patients. The presence of a left atrial (LA) thrombus was excluded by trans-esophageal echocardiography. All antiarrhythmic drugs were discontinued for a period corresponding to at least five half-lives. In total, 58 patients (29.0%) were taking amiodarone, which was discontinued for at least 4 weeks prior to the procedure. Anticoagulation therapy was maintained before catheter ablation.

Electrophysiologic mapping and radiofrequency catheter ablation
---------------------------------------------------------------

Intracardiac electrograms were recorded using the Prucka Cardio Lab™ electrophysiology system (General Electric Health Care System Inc., Milwaukee, WI, USA), and catheter ablation was performed in all patients using 3D electroanatomical mapping (St. Jude Medical Inc., Minnetonka, MN, USA) merged with 3D spiral CT. We used an open irrigated-tip catheter (Celsius, Johnson & Johnson Inc., Diamond Bar, CA, USA; Coolflex, St. Jude Medical Inc., Minnetonka, MN, USA; 30-35 W; 47℃) to deliver RF energy for ablation (Stockert generator, Biosense Webster Inc.; Diamond Bar, CA, USA). All patients initially underwent circumferential PV isolation and bi-directional block of the cavo-tricuspid isthmus. For patients with PeAF, we added the roof line, posterior inferior line, and anterior line[@B10] as a standard lesion set. All procedures were conducted by two operators with over 10 years of experience.

Post-procedural protocol for IRAPB provocation
----------------------------------------------

[Fig. 1](#F1){ref-type="fig"} summarizes the study protocol. After a standard procedure, AF or AT was induced by 10-second high-current burst pacing (10 mA, pulse width 5 ms, Bloom Associates, Denver, CO, USA) from the high right atrial (RA) electrodes. This commenced at a pacing cycle length of 250 ms and was gradually reduced to 120 ms as previously described ([Fig. 2A](#F2){ref-type="fig"}).[@B11] We initiated isoproterenol (5 µg/min) infusion for at least 3 minutes before induction and maintained this for 3 minutes after the induction of AF or AT. Then, internal cardioversion was performed by utilizing biphasic shock (2-15 J) with R wave synchronization (Lifepak12, Physiocontrol Ltd., Redmond, WA, USA) using an anodal decapolar catheter (WOVEN diagnostic catheter, Bard Electrophysiology, Lowell, MA, USA) in the RA and a cathodal duo-decapolar catheter (St. Jude Medical Inc., Minnetonka, MN, USA) in the coronary sinus (CS) ([Fig. 2B](#F2){ref-type="fig"}). After successful electrical cardioversion, we stopped isoproterenol infusion and waited for 10 minutes to map IRAPBs or immediate recurrence of AF originating from the non-PV foci ([Fig. 2C](#F2){ref-type="fig"}). All mappable IRAPBs (≥6/min) or APBs triggering AF were mapped and ablated during the waiting period in the IRAPB provocation group. If AF recurred immediately (8 of 100) or during the mapping of IRAPBs (5 of 100) after cardioversion, we repeated internal cardioversion and attempted to ablate all mappable frequent IRAPBs.

Post-ablation follow-up
-----------------------

Patients were discharged without any anti-arrhythmic drugs and asked to visit the outpatient clinic at 1, 3, 6, and 12 months after RFCA and every 6 months thereafter for follow-up. Electrocardiography (ECG) was performed at each visit or anytime the patient reported palpitations. A Holter ECG (24-hour or 48-hour) and/or event recorder was evaluated at 3, 6, and 12 months after RFCA and every 6 months thereafter for at least 2 years, according to the 2012 HRS/EHRA/ECAS Expert Consensus Statement guidelines.[@B12] We defined recurrence of AF as any episode of AF or AT with a duration of at least 30 sec.[@B13] If any ECG documented an AF episode within the 3-month blanking period during follow-up, the patient was diagnosed with an early recurrence. Any AF recurrence thereafter was diagnosed as clinical recurrence,[@B13] and antiarrhythmic medications were prescribed.

Data analyses
-------------

We compared clinical and electroanatomical markers in patients who experienced recurrence of AF with those in patients who remained in sinus rhythm. Data are expressed as mean±standard deviation. Statistical significance of the comparisons was assessed using Student\'s t-test, Fisher\'s exact test, and Kaplan-Meier analysis. A *p*-value of \<0.05 was considered statistically significant.

RESULTS
=======

Mapping and ablation of post-procedural IRAPBs
----------------------------------------------

[Fig. 1](#F1){ref-type="fig"} summarizes the study protocol. Among the 100 patients in the IRAPB provocation group (70 PAF, 30 PeAF), we mapped and ablated IRAPBs in 33 patients, and 67 did not show post-procedural IRAPB after stopping the isoproterenol infusion ([Table 1](#T1){ref-type="table"}). The patients who tested positive for IRAPB had a higher CHADS~2~ score (*p*=0.003), higher prevalence of previous stroke/transient ischemic attack (*p*=0.002), higher frequency of sinus node dysfunction (*p*=0.025), and a larger left atrial volume index (LAVI; *p*\<0.001) than those who did not. [Fig. 3A](#F3){ref-type="fig"} shows the 44 sites for IRAPBs and additional ablation in 33 patients with positive IRAPB, with locations as follows: superior vena cava (n=12), interatrial septum (n=11), CS ostium (n=10), ligament of Marshall (n=6), crista terminalis (n=3), and LA posterior wall (n=2, one PAF and one PeAF). The RA volume index of the patients with RA-origin IRAPB (21.1±5.6 mL/m^2^) tended to be greater than those with LA origin IRAPB (19.5±4.6 mL/m^2^) without statistical significance (*p*=0.462). In patients with frequent and uni-focal IRAPBs, 3D-electroanatomical mapping was utilized for accurate mapping of non-PV foci or recovered conduction at linear ablation sites ([Fig. 3B](#F3){ref-type="fig"}). The patients who underwent IRAPB ablation required a significantly longer procedure time (*p*=0.001) and ablation time (*p*=0.038) than those without IRAPB ([Table 1](#T1){ref-type="table"}). However, additional ablation for IRAPBs did not increase the procedure-related complication rate (*p*=0.732).

Presence of post-procedural IRAPBs is associated with higher clinical recurrence rate
-------------------------------------------------------------------------------------

During 18.0±6.6 months of follow-up, the early recurrence rate and clinical recurrence rate were 19% and 15%, respectively, for the IRAPB-provocation group. Among 51 patients with positive post-procedural inducibility before isoproterenol infusion, there was no significant difference in recurrence rates with respect to the type of induced atrial tachyarrhythmias (AF vs. AT; *p*=0.694) ([Table 2](#T2){ref-type="table"}). However, the patients with positive IRAPB showed a significantly higher early recurrence rate (36.4% vs. 10.4%; *p*=0.002) and clinical recurrence rate (27.3% vs. 9.0%; *p*=0.016) than those with negative IRAPBs, despite additional ablation and a longer procedure time (*p*=0.001) ([Table 1](#T1){ref-type="table"}). On multivariate logistic regression analysis, IRAPB (β=1.398; odds ratio=4.046; 95% confidence interval 1.14-14.39; *p*=0.031) was independently associated with clinical recurrence after RFCA of AF ([Table 3](#T3){ref-type="table"}). [Table 3](#T3){ref-type="table"} also shows that the type of induced atrial tachyarrhythmias, AT (*p*=0.308) or AF (*p*=0.422), was not associated with clinical recurrence. Kaplan-Meier analysis showed consistently worse clinical outcome in patients with positive IRAPBs after the procedure (log rank, *p*=0.007) ([Fig. 3C](#F3){ref-type="fig"}).

IRAPB provocation and ablation results in better clinical outcome of AF ablation
--------------------------------------------------------------------------------

We compared patient characteristics, procedure time, procedure-related complication rate, and clinical outcome between the patients with IRAPB provocation and age-, sex-, and AF-type-matched patients who completed the procedure without an induction test (No-Test group) ([Table 4](#T4){ref-type="table"}). The baseline characteristics, LA diameter (*p*=0.187), LAVI (*p*=0.105), procedure times (*p*=0.540), ablation times (*p*=0.848), and procedure-related complication rates (*p*=0.702), were not significantly different between the two groups. However, the clinical recurrence rate (15.0% vs. 28.0%; *p*=0.025) was significantly lower in the IRAPB provocation and ablation group than in the No-Test group. Ka-plan-Meier AF-free survival analysis indicated a consistently better clinical outcome in the IRAPB provocation group than in the No-Test group (log rank, *p*=0.038) ([Fig. 3D](#F3){ref-type="fig"}).

DISCUSSION
==========

In the current study, we reported the potential usefulness of post-procedural IRAPB provocation and additional ablation during AF catheter ablation. The patients who showed post-procedural IRAPB under isoproterenol had a clearly higher clinical recurrence rate of AF than those without IRAPB. However, clinical outcome was better in patients with routine post-procedural IRAPB provocation and additional ablation than in those who completed the procedure without an induction test. This study revealed the importance of remaining non-PV foci as a mechanism of recurrence after AF catheter ablation. Therefore, a further prospective study with a larger number of patients is warranted to prove whether routine IRAPB provocation facilitates an improved clinical outcome of AF catheter ablation.

Role of post-procedural detection of AF triggers or substrate
-------------------------------------------------------------

AF is generally a progressive disease, and the mechanism for generation of AF is not yet fully understood.[@B1][@B14] Coumel[@B15][@B16] suggested that trigger factors or trigger foci initiate AF, and arrhythmic substrate leads to its persistence. In this study, we explored the clinical significance of post-procedural tests for AF triggers or IRAPB. It is known that 70-90% of AF triggers exist around PVs in patients with PAF; however, non-PV foci are more common in those with PeAF.[@B4][@B5][@B6] Generally, PV isolation at the level of the PV antrum is a cornerstone of catheter ablation for AF.[@B17][@B18][@B19] In this study, by isolating PVs during the procedure, all post-procedural IRAPBs arose from non-PV foci. Although the presence of IRAPBs from these non-PV foci clearly worsened the clinical outcome of AF ablation, additional ablation targeting IRAPB might result in a lower recurrence rate than that of the No-Test group. Therefore, remaining non-PV-origin IRAPB may play an important role in the recurrence mechanism of AF in the No-Test group.

Clinical significance of non-PV foci
------------------------------------

APBs that trigger AF frequently arise from PVs,[@B20] and cardiac autonomic nerves mainly connect to the heart along the PV antral area.[@B4][@B21][@B22] Therefore, bi-antral PV isolation is effective for the elimination of PV triggers,[@B23][@B24] cardiac autonomic denervation,[@B25] and substrate modification. However, PV isolation may not be sufficient to control AF due to the presence of non-PV foci or atrial substrate remodeling, particularly in patients with PeAF.[@B26][@B27] Clinically, complex fractionated atrial electrograms (CFAEs) are known to play a role in maintaining AF[@B28][@B29] and act as a target for AF catheter ablation.[@B29][@B30] Verma, et al.[@B31] considered CFAE ablation to be a non-PV substrate and a trigger of ablation, and Lemery, et al.[@B32] co-localized the area of CFAE and cardiac autonomic ganglionated plexi by nerve stimulation. However, CFAE includes both the active driver of AF and passive wave breakers, and CFAE-guided AF ablation carries the risk of unnecessary cardiac tissue damage. In this study, we ablated non-PV foci targeting post-cardioversion IRAPBs and demonstrated a better clinical outcome.

Mapping and ablation technique for non-PV foci
----------------------------------------------

We previously reported that an excessively long ablation dura-tion for substrate modification results in a poor clinical outcome.[@B33][@B34] Therefore, limited and sophisticated ablation for non-PV foci based on post-procedural IRAPB might be beneficial for a better clinical outcome. However, detection and ablation of non-PV foci are not simple. We targeted non-PV foci immediately after cardioversion under isoproterenol (5 µg/min) infusion. As we adhered to the linear ablation strategy, including the anterior line[@B10] in patients with PeAF, re-initiation of AF was uncommon (8%) after cardioversion and cessation of isoproterenol infusion, and most non-PV foci remained as frequent APBs. We were able to map those non-PV IRAPBs based on the areas defined by linear ablation lines.[@B11] Quick and limited 3D activation mapping utilizing a multi-electrode catheter was useful for accurate mapping and limited ablation of frequent non-PV-origin APBs in certain patients. We mapped and ablated IRAPBs during the isoproterenol cooling-down period until no APBs appeared.

Limitations
-----------

The patients included in this study were a highly selective group referred for RFCA, and the number of patients was limited. As this was a retrospective single-center study, there might have been a selection bias, despite comparing two groups matched for age, sex, and AF type. Considering that most IRAPBs were mapped and ablated within 10 minutes after stopping isoproterenol infusion, infrequent IRAPBs, multi-focal APBs, and catecholamine-insensitive APBs may not have been eliminated in this study protocol. In addition, we did not challenge isoproterenol again after IRAPB ablation.

Conclusion
----------

The patients who showed post-procedural IRAPB under isoproterenol had a clearly higher clinical recurrence rate of AF. However, careful mapping and ablation for post-procedural IRAPB safely resulted in a better clinical outcome without requiring a longer procedure time compared to those who completed the procedure without an induction test. Therefore, a future prospective study with a larger number of patients is warranted to determine whether routine IRAPB provocation facilitates an improved clinical outcome of AF catheter ablation.
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![Diagram of study protocol. We compared the clinical efficacy of post-procedural provocation for immediate recurrence of atrial premature beats (IRAPBs) under isoproterenol and additional ablation targeting these APBs (n=100) with 100 age-, sex-, and AF-type-matched patients who completed the procedure without an induction test (No-Test group). CL, cycle length; RFCA, radiofrequency catheter ablation; AF, atrial fibrillation; AT, atrial tachycardia.](ymj-57-72-g001){#F1}

![(A) Inducibility test by high-current HRA pacing for 10 sec. AF or AT maintenance longer than 3 min was considered positive inducibility. (B) Catheter position for mapping and cardioversion. For the IRAPB test, we delivered internal cardioversion shock from HRA to CS. (C) An example of IRAPB after cardioversion under isoproterenol infusion. CS, coronary sinus; HRA, high right atrium; LAO, left anterior oblique view; RV, right ventricle; AF, atrial fibrillation; AT, atrial tachycardia; IRAPB, immediate recurrence of atrial premature beat.](ymj-57-72-g002){#F2}

![(A) Locations of post-procedural IRAPBs and additional ablation sites (black circles). White circles indicate the standard ablation sites for PAF. (B)Mapping and ablation of post-procedural IRAPB utilizing 3D activation map. Quick activation mapping by multipolar catheter revealed non-PV foci located on LA posterior wall (white dots) and conduction gap at posterior inferior linear ablation site. We eliminated IRAPBs and ablation gap on posterior inferior line concomitantly. (C) Kaplan-Meier curve for AF-free survival comparing patients with post-procedural IRAPBs to those without IRAPBs. (D) Kaplan-Meier graph of AF-free survival comparing the IRAPB provocation group to the No-Test group. IRAPBs, immediate recurrence of atrial premature beats; 3D, three-dimensional; PV, pulmonary vein; LA, left atrial; AF, atrial fibrillation; PAF, paroxysmal AF.](ymj-57-72-g003){#F3}

###### Characteristics of IRAPB Provocation Group Depending on the Presence of IRAPBs and Additional Ablation

![](ymj-57-72-i001)

  Variables                                IRAPB (+) (n=33)   IRAPB (-) (n=67)   *p* value
  ---------------------------------------- ------------------ ------------------ -----------
  Male, n (%)                              22 (66.7)          54 (80.6)          0.128
  Patient age (yrs)                        57.6±9.5           56.6±11.7          0.692
  PAF, n (%)                               20 (60.6)          50 (74.6)          0.153
  BMI (kg/m^2^)                            25.0±3.0           24.1±2.6           0.183
  CHADS~2~ score, n (%)                    1.1±1.1            0.6±0.8            0.003
   Congestive heart failure                0 (0.0)            2 (3.0)            0.321
   Hypertension                            17 (51.5)          26 (38.8)          0.232
   Age ≥75 yrs                             1 (3.0)            1 (1.5)            0.610
   Diabetes                                6 (18.2)           5 (7.5)            0.109
   Stroke/TIA                              7 (21.2)           2 (3.0)            0.002
  Sinus node dysfunction, n (%)            5 (15.2)           2 (3.0)            0.025
  LA diameter (mm)                         41.1±4.1           39.1±4.8           0.052
  LA volume index (mL/m^2^)                36.2±11.2          28.2±8.5           \<0.001
  LV EF (%)                                64.5±6.0           64.1±8.1           0.806
  E/Em                                     9.7±3.6            8.9±3.0            0.278
  Procedure time (min)                     201.0±34.8         174.3±30.7         0.001
  Ablation time (sec)                      5280.0±1470.9      4617.0±1304.4      0.038
  Procedure-related complications, n (%)   1 (3.0)            3 (4.5)            0.732
  Follow-up duration (months)              17.4±5.7           18.1±7.4           0.643
  Early recurrence rates (%)               36.4               10.4               0.002
  Clinical Recurrence rates (%)            27.3               9.0                0.016

BMI, body mass index; E/Em, ratio of early mitral inflow peak velocity and Doppler-derived early diastolic mitral annular velocity; IRAPB, immediate recurrence of atrial premature beats after cardioversion; LA, left atrium; LV EF, left ventricular ejection fraction; PAF, paroxysmal atrial fibrillation; TIA, transient ischemic attack.

###### Clinical Outcomes Depending on the Type of Post-Procedural Atrial Tachyarrhythmias (AT/AF) Induced by High-Current Rapid Atrial Pacing

![](ymj-57-72-i002)

  Variables                       AT induction (n=35)   AF induction (n=16)   *p* value
  ------------------------------- --------------------- --------------------- -----------
  Follow-up duration (month)      18.2±6.1              17.3±4.9              0.625
  Early recurrence rates (%)      28.6                  31.3                  0.849
  Clinical recurrence rates (%)   20.0                  25.0                  0.694

AF, atrial fibrillation; AT, atrial tachycardia.

###### Factors Associated with Clinical Recurrence after Radiofrequency Catheter Ablation (Logistic Regression Analyses)

![](ymj-57-72-i003)

  Variables                            Univariate analysis   Multivariate analysis                                
  ------------------------------------ --------------------- ----------------------- ------- ------- ------------ -------
  PAF                                  0.590                 0.19-1.84               0.363   0.986   0.26-3.74    0.983
  Male                                 1.312                 0.34-5.10               0.695   1.373   0.29-6.56    0.691
  Age (yrs)                            1.014                 0.96-1.07               0.596   1.001   0.94-1.07    0.967
  Diabetes                             4.052                 1.02-16.13              0.047   3.205   0.71-14.41   0.129
  Pre-RFCA LA volume index (mL/m^2^)   1.046                 0.99-1.11               0.132                        
  Pre-RFCA LV EF (%)                   1.044                 0.96-1.13               0.304   1.018   0.93-1.12    0.711
  Pre-RFCA E/Em                        1.009                 0.85-1.21               0.919   0.983   0.79-1.22    0.878
  AT or AF induction (+)               3.094                 0.91-10.49              0.070                        
   AT induction (+)                    1.781                 0.59-5.41               0.308                        
   AF induction (+)                    1.625                 0.50-5.31               0.422                        
  IRAPB (+)                            3.812                 1.22-11.87              0.021   4.046   1.14-14.39   0.031

AF, atrial fibrillation; AT, atrial tachycardia; CI, confidence interval; E/Em, ratio of early mitral inflow peak velocity and Doppler-derived early diastolic mitral annular velocity; IRAPB, immediate recurrence of atrial premature beats; LA, left atrial; LV EF, left ventricular ejection fraction; OR, odds ratio; PAF, paroxysmal atrial fibrillation; RFCA, radiofrequency catheter ablation.

###### Characteristics Comparing IRAPB Provocation/Ablation Group vs. No-Test Group
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  Variables                                All (n=200)     Provocation of IRAPB (n=100)   No test (n=100)   *p* value
  ---------------------------------------- --------------- ------------------------------ ----------------- -----------
  Male, n (%)                              153 (76.5)      76 (76.0)                      77 (77.0)         0.868
  Age (yrs)                                57.4±11.1       57.0±11.0                      57.9±11.2         0.551
  PAF, n (%)                               134 (67.0)      70 (70.0)                      64 (64.0)         0.369
  BMI (kg/m^2^)                            24.9±3.9        24.5±2.8                       25.3±4.7          0.233
  CHADS~2~ score, n (%)                    0.8±1.0         0.8±0.9                        0.9±1.0           0.309
   Congestive heart failure                6 (3.0)         2 (2.0)                        4 (4.0)           0.410
   Hypertension                            92 (46.0)       43 (43.0)                      49 (49.0)         0.397
   Age ≥75 yrs                             4 (2.0)         2 (2.0)                        2 (2.0)           1.000
   Diabetes                                28 (14.0)       11 (11.0)                      17 (17.0)         0.223
   Stroke/TIA                              18 (9.0)        9 (9.0)                        9 (9.0)           1.000
  Sinus node dysfunction, n (%)            10 (5.0)        7 (7.0)                        3 (3.0)           0.196
  LA diameter (mm)                         40.2±4.8        39.8±4.6                       40.7±5.0          0.187
  LA volume index (mL/m^2^)                32.0±10.2       30.8±10.1                      33.2±10.2         0.105
  LV EF (%)                                63.6±7.7        64.2±7.5                       63.0±7.9          0.275
  E/Em                                     9.7±4.3         9.2±3.2                        10.2±5.1          0.107
  RFCA procedural parameters                                                                                
   Procedure time (min)                    180.9±34.5      182.5±34.2                     179.4±34.8        0.540
   Ablation time (sec)                     4803.5±1286.4   4822.8±1384.4                  4786.4±1199.7     0.848
  Ablation strategy, n (BDB rate, %)                                                                        
   PVI                                     200 (100.0)     100 (100.0)                    100 (100.0)       \>0.999
   CTI block                               192 (100.0)     94 (100.0)                     98 (100.0)        0.155
   Roof line                               66 (97.0)       30 (100.0)                     36 (94.4)         0.369
   Posterior-inferior line                 51 (71.9)       29 (66.7)                      22 (76.5)         0.258
   Anterior linear line                    53 (67.9)       26 (57.1)                      27 (78.6)         0.873
  Procedure-related complications, n (%)   7 (3.5)         4 (4.0)                        3 (3.0)           0.702
   Hemopericardium                         4 (2.0)         1 (1.0)                        3 (3.0)           0.315
   Mild PV stenosis                        1 (0.5)         1 (1.0)                        0 (0.0)           0.319
   Groin hematoma                          2 (1.0)         2 (2.0)                        0 (0.0)           0.157
  Follow-up duration (months)              18.0±6.6        17.9±6.9                       18.2±6.4          0.694
  Early recurrence rates (%)               30.5            19.0                           42.0              \<0.001
  Clinical recurrence rates (%)            21.5            15.0                           28.0              0.025

BMI, body mass index; E/Em, ratio of early mitral inflow peak velocity and Doppler-derived early diastolic mitral annular velocity; IRAPB, immediate recurrence of atrial premature beats after cardioversion; LA, left atrium; LV EF, left ventricular ejection fraction; PAF, paroxysmal atrial fibrillation; PV, pulmonary vein; PVI, pulmonary vein isolation; TIA, transient ischemic attack; BDB, bidirectional block; RFCA, radiofrequency catheter ablation; CTI, cavotricuspid isthmus.
